Lori R Guelman, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Adventist Health Sonora · Community Hospital of the Monterey Peninsula · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Lori R Guelman’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence C17970 · Cancelled
Licence status: Cancelled · since 1956 · Jefferson Medical College of Thomas Jefferson University.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health SonoraSonora, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Postoperative wound dehiscence rate: 3.5 (2.04 to 4.96) · 288 cases, Jul 2022 – Jun 2024Worse than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 1.3 (1 to 1.6) · 1,004 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.185, Oct 2024 – Sep 2025
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Sonora
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 1 better, 7 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative wound dehiscence rateComplications and deaths | 3.5 (2.04 to 4.96) · 288 cases | Worse | Jul 2022 – Jun 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.6) · 1,004 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.185 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.15 (0.14 to 2.16) · 582 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.5 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 182.91 (123.44 to 242.37) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9 · 125 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.7 · 236 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15 · 433 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,364 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.39) · 3,671 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.07 to 0.48) · 3,602 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.24 to 5.59) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.59 (0.98 to 4.2) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.97 (0 to 16.16) · 306 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.72 (1.85 to 9.58) · 277 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.06) · 2,750 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.614 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 209 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 12.6 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -23.8 · 255 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.4 · 455 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 381 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6 (4.3 to 8.1) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (9.1 to 14.7) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.3) · 1,835 cases | No different | Jan 2022 – Dec 2024 |
What patients said (326 patients answered, 21% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$27,082
Medicare paid this office $27,082 for 296 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 86 | $6,156 | $64 |
| Biopsy of prostate gland | 51 | $4,867 | $95 |
| Return visit (30+ min) | 44 | $4,408 | $100 |
| New patient visit (60+ min) | 15 | $1,539 | $103 |
| Instillation of anti-cancer drug into bladder | 21 | $1,508 | $31 |
See all 11 services
| Short return visit (20+ min) | 86 | $6,156 | $64 |
| Biopsy of prostate gland | 51 | $4,867 | $95 |
| Return visit (30+ min) | 44 | $4,408 | $100 |
| New patient visit (60+ min) | 15 | $1,539 | $103 |
| Instillation of anti-cancer drug into bladder | 21 | $1,508 | $31 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $1,406 | $100 |
| Return visit (30+ min) | 15 | $1,119 | $70 |
| Insertion of temporary bladder tube | 16 | $721 | $18 |
| Ultrasound scan of pelvic region through rectum | 25 | $624 | $25 |
| Short return visit (20+ min) | 16 | $605 | $36 |
| Insertion of temporary bladder tube | 15 | $340 | $15 |
Who their Medicare patients are
296 Original Medicare patients in 2024. Average age 74 · Under 65 4% · 85 and older 7% · Women 12% · Also on Medicaid 15% · Health risk score 1.50. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 71% · Cancer 67% · Coronary heart disease 29% · Diabetes 26% · Chronic kidney disease 24% · Atrial fibrillation 18% · Heart failure 12% · Depression 11% · COPD 8% · Stroke 6%.
The office billed $223,774, Medicare allowed $37,499 and paid $27,082; for 444 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 296 | 444 | 74 | 1.50 | $223,774 | $27,082 |
| 2023 | 271 | 365 | 72 | 2.02 | $193,823 | $22,978 |
| 2022 | 208 | 333 | 72 | 1.54 | $154,972 | $20,283 |
| 2021 | 129 | 183 | 74 | 1.06 | $103,289 | $14,340 |
| 2020 | 135 | 170 | 74 | 1.61 | $46,106 | $6,625 |
| 2019 | 389 | 769 | 75 | 1.70 | $146,349 | $27,396 |
| 2018 | 390 | 877 | 75 | 1.60 | $184,283 | $28,785 |
| 2017 | 357 | 825 | 73 | 1.46 | $158,087 | $24,569 |
| 2016 | 316 | 754 | 74 | 1.45 | $158,198 | $23,627 |
| 2015 | 337 | 776 | 73 | 1.67 | $148,156 | $26,685 |
| 2014 | 335 | 896 | 73 | 1.50 | $170,364 | $31,332 |
| 2013 | 251 | 772 | 71 | 1.46 | $169,299 | $23,769 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 60 | $4,691 | $69 |
| New patient visit (60+ min) | 30 | $3,729 | $124 |
| Short return visit (20+ min) | 66 | $3,669 | $48 |
| Biopsy of prostate gland | 34 | $3,371 | $99 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 29 | $3,249 | $112 |
| Long return visit (40+ min) | 11 | $1,331 | $111 |
| Instillation of anti-cancer drug into bladder | 18 | $679 | $25 |
| Ultrasonic guidance for needle placement | 23 | $542 | $24 |
| Short return visit | 11 | $306 | $28 |
2022: 5 services
| Return visit (30+ min) | 74 | $6,077 | $65 |
| New patient visit (60+ min) | 32 | $3,945 | $123 |
| Short return visit (20+ min) | 57 | $3,193 | $46 |
| Instillation of anti-cancer drug into bladder | 26 | $2,334 | $33 |
| Long return visit (40+ min) | 19 | $2,055 | $108 |
2021: 3 services
| Return visit (30+ min) | 64 | $6,330 | $68 |
| New patient visit (60+ min) | 31 | $3,911 | $126 |
| Long return visit (40+ min) | 23 | $2,675 | $107 |
2020: 4 services
| Short return visit (20+ min) | 58 | $1,936 | $33 |
| New patient visit (45+ min) | 14 | $1,431 | $102 |
| Return visit (30+ min) | 30 | $1,266 | $42 |
| Insertion of lower leg neurostimulator electrode | 13 | $510 | $17 |
2019: 6 services
| Short return visit (20+ min) | 232 | $10,858 | $36 |
| Return visit (30+ min) | 111 | $6,952 | $56 |
| Insertion of lower leg neurostimulator electrode | 27 | $3,173 | $21 |
| New patient visit (30+ min) | 56 | $3,030 | $54 |
| Simple change of bladder tube | 11 | $1,480 | $39 |
| Short return visit | 40 | $1,041 | $18 |
2018: 7 services
| Short return visit (20+ min) | 206 | $9,057 | $36 |
| Return visit (30+ min) | 107 | $7,156 | $56 |
| Insertion of lower leg neurostimulator electrode | 29 | $4,366 | $22 |
| Short return visit | 87 | $2,455 | $17 |
| New patient visit (30+ min) | 37 | $2,037 | $55 |
| Simple change of bladder tube | 14 | $1,676 | $40 |
| Electronic assessment of bladder emptying | 23 | $142 | $6 |
2017: 7 services
| Short return visit (20+ min) | 194 | $8,171 | $34 |
| Return visit (30+ min) | 81 | $4,431 | $52 |
| Short return visit | 133 | $3,396 | $18 |
| Insertion of lower leg neurostimulator electrode | 25 | $3,213 | $22 |
| New patient visit (30+ min) | 32 | $1,674 | $52 |
| Electronic analysis of implanted neurostimulator generator with simple spinal cord or peripheral nerve stimulator programming | 11 | $433 | $29 |
| Electronic assessment of bladder emptying | 16 | $97 | $5 |
2016: 6 services
| Short return visit (20+ min) | 186 | $7,943 | $35 |
| Return visit (30+ min) | 74 | $5,012 | $56 |
| Insertion of lower leg neurostimulator electrode | 18 | $3,056 | $21 |
| Short return visit | 97 | $2,427 | $17 |
| New patient visit (30+ min) | 28 | $1,499 | $54 |
| Electronic assessment of bladder emptying | 23 | $139 | $6 |
2015: 6 services
| Short return visit (20+ min) | 187 | $8,084 | $35 |
| New patient visit (45+ min) | 71 | $6,342 | $89 |
| Return visit (30+ min) | 67 | $3,766 | $54 |
| Short return visit | 104 | $3,283 | $17 |
| Insertion of lower leg neurostimulator electrode | 11 | $1,677 | $22 |
| Electronic assessment of bladder emptying | 37 | $238 | $6 |
2014: 6 services
| Short return visit (20+ min) | 176 | $8,637 | $35 |
| New patient visit (45+ min) | 90 | $8,005 | $89 |
| Return visit (30+ min) | 75 | $4,769 | $59 |
| Short return visit | 103 | $4,210 | $18 |
| Insertion of lower leg neurostimulator electrode | 12 | $1,782 | $21 |
| Electronic assessment of bladder emptying | 50 | $357 | $6 |
2013: 7 services
| New patient visit (45+ min) | 64 | $5,723 | $89 |
| Short return visit (20+ min) | 104 | $4,786 | $34 |
| Short return visit | 119 | $3,243 | $17 |
| Insertion of lower leg neurostimulator electrode | 14 | $3,098 | $21 |
| Return visit (30+ min) | 44 | $2,509 | $53 |
| Simple bladder irrigation and/or instillation | 15 | $2,160 | $29 |
| Electronic assessment of bladder emptying | 43 | $266 | $6 |
Medicaid work
$549 in 2019
Medicaid paid $549 for 79 billed services this clinician did in 2019, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 66 | $479 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 13 | $70 |
| 2019 | 79 | 2 | 13 | $549 |
| 2018 | 91 | 2 | 22 | $543 |
See the largest Medicaid services in earlier years
2018
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 76 | $461 |
| Hospital outpatient clinic visit for assessment and management of a patient | 15 | $82 |
Drugs they prescribed that Part D paid
$9,425
Pharmacies billed $9,425 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 254) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
246 generic and fewer than 11 brand-name prescriptions · $9,425 in drug cost · 58 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tamsulosin | 54 | $1,881 | $18 |
| Finasteride | 26 | $841 | $15 |
| Nitrofurantoin Mono-Macro | 11 | $183 | $17 |
| Amoxicillin-Clavulanate Potass | 13 | $90 | $6 |
| Cephalexin | 12 | $48 | $4 |
Year by year
| 2024 | 254 | 143 | 0% (0) | None | $9,425 |
| 2023 | 132 | 86 | None | None | $6,108 |
| 2022 | 104 | 66 | None | None | $3,387 |
| 2021 | 109 | 68 | None | None | $5,424 |
| 2020 | 485 | 169 | 0% (0) | None | $109,070 |
| 2019 | 1,300 | 302 | None | None | $283,026 |
| 2018 | 1,281 | 289 | None | 32% | $213,678 |
| 2017 | 1,101 | 271 | None | 27% | $166,192 |
| 2016 | 1,089 | 251 | None | None | $160,167 |
| 2015 | 1,080 | 232 | 0% (0) | None | $153,548 |
| 2014 | 898 | 201 | None | None | $108,838 |
| 2013 | 646 | 159 | None | None | $83,515 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Tamsulosin | 65 | $1,924 | $30 |
| Finasteride | 13 | $208 | $16 |
| Sulfamethoxazole-Trimethoprim | 12 | $66 | $5 |
2022: 2 drugs
| Tamsulosin | 44 | $944 | $21 |
| Finasteride | 20 | $386 | $19 |
2021: 2 drugs
| Tamsulosin | 59 | $1,463 | $25 |
| Finasteride | 15 | $572 | $38 |
2020: 12 drugs
| Myrbetriq | 75 | $60,188 | $803 |
| Estring | 15 | $7,272 | $485 |
| Premarin | 11 | $4,276 | $389 |
| Estradiol | 11 | $2,468 | $224 |
| Methenamine Hippurate | 22 | $2,284 | $104 |
| Trospium Chloride | 14 | $2,055 | $147 |
| Tamsulosin | 91 | $1,619 | $18 |
| Oxybutynin Chloride Er | 17 | $1,515 | $89 |
| Finasteride | 95 | $1,410 | $15 |
| Gentamicin Sulfate | 15 | $1,202 | $80 |
| Cephalexin | 16 | $103 | $6 |
| Sodium Chloride | 12 | $42 | $3 |
2019: 22 drugs
| Myrbetriq | 244 | $165,293 | $677 |
| Elmiron | 13 | $25,190 | $1,938 |
| Premarin | 51 | $19,217 | $377 |
| Methenamine Hippurate | 79 | $8,723 | $110 |
| Estring | 16 | $7,181 | $449 |
| Estrace | 16 | $5,575 | $348 |
| Tamsulosin | 232 | $4,577 | $20 |
| Estradiol | 16 | $3,841 | $240 |
| Finasteride | 189 | $3,831 | $20 |
| Oxybutynin Chloride Er | 46 | $2,788 | $61 |
| Trospium Chloride | 18 | $2,273 | $126 |
| Dutasteride | 18 | $2,131 | $118 |
| Yuvafem | 13 | $1,559 | $120 |
| Testosterone Cypionate | 12 | $817 | $68 |
| Cephalexin | 99 | $709 | $7 |
| Amitriptyline | 19 | $536 | $28 |
| Doxazosin Mesylate | 16 | $469 | $29 |
| Oxybutynin Chloride | 11 | $403 | $37 |
| Nitrofurantoin Mono-Macro | 23 | $377 | $16 |
| Nitrofurantoin | 11 | $333 | $30 |
| Sodium Chloride | 17 | $145 | $9 |
| Sulfamethoxazole-Trimethoprim | 16 | $73 | $5 |
2018: 25 drugs
| Myrbetriq | 201 | $102,218 | $509 |
| Elmiron | 22 | $33,094 | $1,504 |
| Premarin | 28 | $11,458 | $409 |
| Estring | 26 | $11,117 | $428 |
| Vesicare | 18 | $8,114 | $451 |
| Methenamine Hippurate | 61 | $5,416 | $89 |
| Tamsulosin | 239 | $4,476 | $19 |
| Estrace | 12 | $4,143 | $345 |
| Finasteride | 153 | $2,889 | $19 |
| Trospium Chloride | 24 | $2,515 | $105 |
| Oxybutynin Chloride Er | 47 | $2,402 | $51 |
| Estradiol | 11 | $2,340 | $213 |
| Dutasteride | 16 | $1,466 | $92 |
| Yuvafem | 13 | $1,397 | $107 |
| Methenamine Mandelate | 12 | $1,135 | $95 |
| Cephalexin | 103 | $890 | $9 |
| Gentamicin Sulfate | 17 | $882 | $52 |
| Amitriptyline | 33 | $762 | $23 |
| Nitrofurantoin | 17 | $430 | $25 |
| Doxazosin Mesylate | 19 | $423 | $22 |
| Nitrofurantoin Mono-Macro | 14 | $279 | $20 |
| Fluconazole | 21 | $177 | $8 |
| Sodium Chloride | 18 | $168 | $9 |
| Sulfamethoxazole-Trimethoprim | 22 | $116 | $5 |
| Imipramine | 12 | $60 | $5 |
2017: 21 drugs
| Myrbetriq | 126 | $53,639 | $426 |
| Elmiron | 19 | $26,920 | $1,417 |
| Premarin | 45 | $15,883 | $353 |
| Vesicare | 14 | $10,465 | $748 |
| Estrace | 22 | $6,372 | $290 |
| Tamsulosin | 232 | $5,855 | $25 |
| Tolterodine Tartrate Er | 15 | $3,266 | $218 |
| Trospium Chloride | 33 | $2,815 | $85 |
| Oxybutynin Chloride Er | 65 | $2,793 | $43 |
| Finasteride | 121 | $2,036 | $17 |
| Methenamine Hippurate | 15 | $1,862 | $124 |
| Monurol | 21 | $1,853 | $88 |
| Methenamine Mandelate | 17 | $1,386 | $82 |
| Cephalexin | 86 | $1,126 | $13 |
| Amitriptyline | 28 | $766 | $27 |
| Testosterone Cypionate | 11 | $388 | $35 |
| Doxazosin Mesylate | 14 | $381 | $27 |
| Sulfamethoxazole-Trimethoprim | 45 | $267 | $6 |
| Nitrofurantoin Mono-Macro | 16 | $221 | $14 |
| Ciprofloxacin | 25 | $116 | $5 |
| Imipramine | 14 | $91 | $6 |
2016: 19 drugs
| Elmiron | 49 | $47,562 | $971 |
| Myrbetriq | 117 | $42,786 | $366 |
| Vesicare | 34 | $14,295 | $420 |
| Premarin | 42 | $12,561 | $299 |
| Tamsulosin | 217 | $5,459 | $25 |
| Trospium Chloride Er | 14 | $3,530 | $252 |
| Estrace | 13 | $3,500 | $269 |
| Oxybutynin Chloride Er | 77 | $3,427 | $45 |
| Tolterodine Tartrate Er | 12 | $3,104 | $259 |
| Trospium Chloride | 28 | $2,413 | $86 |
| Finasteride | 139 | $2,218 | $16 |
| Amitriptyline | 25 | $1,007 | $40 |
| Methenamine Hippurate | 15 | $954 | $64 |
| Cephalexin | 85 | $818 | $10 |
| Doxazosin Mesylate | 18 | $591 | $33 |
| Nitrofurantoin Mono-Macro | 15 | $281 | $19 |
| Sulfamethoxazole-Trimethoprim | 32 | $154 | $5 |
| Imipramine | 19 | $135 | $7 |
| Ciprofloxacin | 11 | $59 | $5 |
2015: 20 drugs
| Myrbetriq | 119 | $36,785 | $309 |
| Elmiron | 33 | $31,349 | $950 |
| Premarin | 83 | $21,539 | $260 |
| Vesicare | 45 | $14,190 | $315 |
| Tamsulosin | 166 | $5,209 | $31 |
| Oxybutynin Chloride Er | 54 | $4,611 | $85 |
| Toviaz | 17 | $4,265 | $251 |
| Tolterodine Tartrate Er | 20 | $3,682 | $184 |
| Vagifem | 15 | $3,334 | $222 |
| Finasteride | 146 | $2,159 | $15 |
| Nitrofurantoin | 29 | $1,195 | $41 |
| Cephalexin | 98 | $1,112 | $11 |
| Amitriptyline | 20 | $581 | $29 |
| Doxazosin Mesylate | 12 | $411 | $34 |
| Nitrofurantoin Mono-Macro | 14 | $301 | $21 |
| Oxybutynin Chloride | 12 | $258 | $21 |
| Sulfamethoxazole-Trimethoprim | 26 | $185 | $7 |
| Ciprofloxacin | 27 | $143 | $5 |
| Imipramine | 13 | $137 | $11 |
| Levofloxacin | 11 | $38 | $3 |
2014: 18 drugs
| Elmiron | 25 | $20,555 | $822 |
| Premarin | 81 | $18,116 | $224 |
| Vesicare | 66 | $16,662 | $252 |
| Myrbetriq | 48 | $13,979 | $291 |
| Avodart | 27 | $7,567 | $280 |
| Toviaz | 23 | $5,789 | $252 |
| Trospium Chloride Er | 11 | $3,496 | $318 |
| Tamsulosin | 145 | $3,054 | $21 |
| Finasteride | 129 | $2,114 | $16 |
| Nitrofurantoin | 29 | $1,268 | $44 |
| Oxybutynin Chloride Er | 23 | $1,123 | $49 |
| Cephalexin | 70 | $625 | $9 |
| Nitrofurantoin Mono-Macro | 13 | $377 | $29 |
| Alfuzosin Hcl Er | 14 | $365 | $26 |
| Amitriptyline | 12 | $247 | $21 |
| Oxybutynin Chloride | 16 | $222 | $14 |
| Sulfamethoxazole-Trimethoprim | 33 | $199 | $6 |
| Ciprofloxacin | 16 | $129 | $8 |
2013: 16 drugs
| Elmiron | 27 | $16,969 | $628 |
| Vesicare | 65 | $16,413 | $253 |
| Premarin | 46 | $8,603 | $187 |
| Myrbetriq | 24 | $5,898 | $246 |
| Toviaz | 17 | $3,787 | $223 |
| Avodart | 19 | $3,599 | $189 |
| Trospium Chloride Er | 13 | $2,955 | $227 |
| Enablex | 15 | $2,680 | $179 |
| Tamsulosin | 94 | $1,911 | $20 |
| Oxybutynin Chloride Er | 32 | $1,863 | $58 |
| Nitrofurantoin | 25 | $1,124 | $45 |
| Finasteride | 30 | $948 | $32 |
| Nitrofurantoin Mono-Macro | 24 | $672 | $28 |
| Cephalexin | 47 | $412 | $9 |
| Sulfamethoxazole-Trimethoprim | 30 | $201 | $7 |
| Ciprofloxacin | 19 | $93 | $5 |
Money from drug and device companies
$109 in 2025
| 2025 | 4 | 4 | None | $109 |
| 2024 | 1 | 1 | None | $18 |
| 2023 | 5 | 7 | None | $572 |
| 2022 | 3 | 3 | None | $295 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Scientific Affairs | Erleada | $36 | 1 payment
|
| Astellas Pharma US | Padcev | $27 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $25 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $22 | 1 payment
|
See all 4 published payments
| Astellas Pharma US | Meals · 2025-11-13 | Padcev | $27 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-27 | Nubeqa | $25 |
| Janssen Scientific Affairs | Meals · 2025-03-15 | Erleada | $36 |
| Tactile Systems Technology | Meals · 2025-03-07 | Flexitouch Plus | $22 |
See earlier years (2024, 2023, 2022)
2024: $18
| Pfizer | Inlyta | $18 | 1 payment
|
2023: $572
| Myriad Genetic Laboratories | Precisetumor | $152 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $128 | 1 payment
|
| Iti | Caplyta | $126 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $124 | 1 payment
|
| Astellas Pharma US | Xtandi | $43 | 1 payment
|
2022: $295
| Neurocrine Biosciences | Ingrezza | $131 | 1 payment
|
| Amgen | Repatha | $125 | 1 payment
|
| Astellas Pharma US | None | $40 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1689850745
- Licence
- CA 17970California C17970: Cancelled
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X); Federal specialty code 363LF0000X (363LF0000X); Federal specialty code 363LP2300X (363LP2300X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-01-18
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.